HomepageAXGN • NASDAQ
add
AxoGen, Inc Common Stock
$Â 13,79
Na sluitingstijd:(0,00%)0,00
$Â 13,79
Gesloten: 27 sep, 16:51:46 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 13,80
Dag-range
$Â 13,58 - $Â 14,06
Jaar-range
$Â 3,45 - $Â 15,08
Beurswaarde
604,41Â mln. USD
Gem. volume
428,84K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 47,91Â mln. | 25,57% |
Bedrijfskosten | 35,77Â mln. | -2,14% |
Netto inkomsten | -1,92Â mln. | 71,16% |
Netto winstmarge | -4,01 | 77,03% |
Winst per aandeel | 0,05 | 266,67% |
EBITDA | 1,30Â mln. | 121,63% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 21,13Â mln. | -38,80% |
Totale activa | 188,93Â mln. | -1,41% |
Totale passiva | 93,24Â mln. | -1,32% |
Totaal aandelenvermogen | 95,69 mln. | — |
Uitstaande aandelen | 43,83 mln. | — |
Koers-boekwaardeverhouding | 6,33 | — |
Rendement op activa | -0,57% | — |
Rendement op kapitaal | -0,64% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -1,92Â mln. | 71,16% |
Operationele kasstroom | 4,16Â mln. | 1.326,37% |
Kasstroom uit beleggingen | -1,23Â mln. | -108,61% |
Kasstroom uit financiering | 544,00K | -39,42% |
Nettomutatie in liquide middelen | 3,48Â mln. | -77,59% |
Vrije kasstroom | 3,60Â mln. | 777,62% |
Over
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Opgericht
2002
Hoofdvestiging
Website
Werknemers
427